Leishmania RNA virus: when the host pays the toll

Mary‐Anne Hartley, Catherine Ronet, Haroun Zangger, Stephen M. Beverley, Nicolás FaselFrontiers in Cellular and Infection Microbiology 2012 · DOI

Abstract

The presence of an RNA virus in a South American subgenus of the Leishmania parasite, L. (Viannia), was detected several decades ago but its role in leishmanial virulence and metastasis was only recently described. In Leishmania guyanensis, the nucleic acid of Leishmania RNA virus (LRV1) acts as a potent innate immunogen, eliciting a hyper-inflammatory immune response through toll-like receptor 3 (TLR3). The resultant inflammatory cascade has been shown to increase disease severity, parasite persistence, and perhaps even resistance to anti-leishmanial drugs. Curiously, LRVs were found mostly in clinical isolates prone to infectious metastasis in both their human source and experimental animal model, suggesting an association between the viral hyperpathogen and metastatic complications such as mucocutaneous leishmaniasis (MCL). MCL presents as chronic secondary lesions in the mucosa of the mouth and nose, debilitatingly inflamed and notoriously refractory to treatment. Immunologically, this outcome has many of the same hallmarks associated with the reaction to LRV: production of type 1 interferons, bias toward a chronic Th1 inflammatory state and an impaired ability of host cells to eliminate parasites through oxidative stress. More intriguing, is that the risk of developing MCL is found almost exclusively in infections of the L. (Viannia) subtype, further indication that leishmanial metastasis is caused, at least in part, by a parasitic component. LRV present in this subgenus may contribute to the destructive inflammation of metastatic disease either by acting in concert with other intrinsic "metastatic factors" or by independently preying on host TLR3 hypersensitivity. Because LRV amplifies parasite virulence, its presence may provide a unique target for diagnostic and clinical intervention of metastatic leishmaniasis. Taking examples from other members of the Totiviridae virus family, this paper reviews the benefits and costs of endosymbiosis, specifically for the maintenance of LRV infection in Leishmania parasites, which is often at the expense of its human host.

Introduction: The Burden of Metastatic Leishmaniasis

Leishmaniasis remains a significant global health challenge, characterized by a wide spectrum of clinical presentations ranging from self-healing skin ulcers to fatal systemic infections. While localized cutaneous leishmaniasis (CL) is the most common form, a subset of patients in South America develops a far more severe manifestation: mucocutaneous leishmaniasis (MCL). In these cases, the parasite metastasizes from the primary skin lesion to the mucous membranes of the nose and mouth, leading to chronic, disfiguring inflammation that is notoriously resistant to standard treatments. For decades, the biological trigger for this metastatic "jump" remained elusive. Recent research into the "hyperpathogen" hypothesis suggests that the architect of this destruction is not the parasite alone, but a double-stranded RNA virus (LRV) residing within it.

The TLR3 Trap: Viral Hijacking of the Immune System

The primary mechanism of LRV-induced virulence lies in its interaction with the human innate immune system. Typically, Toll-like receptor 3 (TLR3) serves as a critical defense mechanism, detecting viral double-stranded RNA (dsRNA) to initiate an antiviral state. However, in the context of Leishmania infection, the parasite utilizes the virus to "trip" this alarm prematurely.

Instead of clearing the infection, the resulting TLR3-mediated hyper-inflammation creates a "cytokine storm" characterized by high levels of pro-inflammatory TNF-α and IFN-γ. This deleterious Th1 extreme prevents the host from effectively clearing the parasite and impairs the ability of host cells to respond to anti-inflammatory signals like IL-10. Essentially, the virus hijacks the host's immune response to promote parasite persistence and disease severity.

Phylogeny and Clinical Correlation

Phylogenetic analysis reveals a striking correlation between the presence of LRV and the clinical outcome of the infection. As illustrated in the following figure, LRV is found almost exclusively within the L. (Viannia) subgenus, which is responsible for the vast majority of MCL cases.

Leishmanial phylogeny and LRV presence across species complexes.

Experimental evidence from animal models supports this correlation. In studies using golden hamsters and TLR3-deficient mice, the absence of the TLR3 receptor completely abolished the increased pathogenicity typically seen in LRV-infected strains. This confirms that the virus-host receptor interaction is the primary driver of clinical severity.

Evolutionary Symbiosis and Virulence Factors

The relationship between LRV and Leishmania is a sophisticated form of mutualism. The virus gains a stable environment and a reliable transmission vehicle, while the parasite gains increased fitness at the expense of the human host. Beyond triggering inflammation, LRV+ strains exhibit enhanced survival mechanisms, such as the increased expression of cytosolic tryparedoxin peroxidase (cTXPNx). This enzyme helps the parasite survive the "oxidative burst" that host macrophages use to destroy pathogens.

Furthermore, the maintenance of the virus appears linked to the parasite's own genetic machinery. Species that have lost their RNA interference (RNAi) pathways seem unable to harbor the virus, suggesting that a functional, finely-tuned RNAi system is necessary to regulate the viral population and prevent it from killing its parasitic host.

Clinical Implications and Future Directions

The discovery of LRV as a driver of metastasis has profound implications for the diagnosis and treatment of leishmaniasis. The presence of the virus has already been linked to increased resistance to pentavalent antimonials, the standard but highly toxic treatment for the disease.

Future clinical strategies could focus on:

  • Rapid Diagnostics: Developing field-deployable tests to detect LRV in primary lesions. Early identification of LRV+ infections would allow clinicians to implement aggressive treatment protocols before metastasis occurs.
  • Antiviral Therapeutics: Exploring whether "curing" the parasite of its viral passenger using specific antivirals could render it less virulent and more susceptible to standard anti-leishmanial drugs.

While LRV is not the only factor involved in metastasis—as evidenced by some metastatic cases in LRV-negative strains like L. panamensis—it represents a major, targetable component of the disease's most destructive forms.

Summary updated

Abstract

The presence of an RNA virus in a South American subgenus of the Leishmania parasite, L. (Viannia), was detected several decades ago but its role in leishmanial virulence and metastasis was only recently described. In Leishmania guyanensis, the nucleic acid of Leishmania RNA virus (LRV1) acts as a potent innate immunogen, eliciting a hyper-inflammatory immune response through toll-like receptor 3 (TLR3). The resultant inflammatory cascade has been shown to increase disease severity, parasite persistence, and perhaps even resistance to anti-leishmanial drugs. Curiously, LRVs were found mostly in clinical isolates prone to infectious metastasis in both their human source and experimental animal model, suggesting an association between the viral hyperpathogen and metastatic complications such as mucocutaneous leishmaniasis (MCL). MCL presents as chronic secondary lesions in the mucosa of the mouth and nose, debilitatingly inflamed and notoriously refractory to treatment. Immunologically, this outcome has many of the same hallmarks associated with the reaction to LRV: production of type 1 interferons, bias toward a chronic Th1 inflammatory state and an impaired ability of host cells to eliminate parasites through oxidative stress. More intriguing, is that the risk of developing MCL is found almost exclusively in infections of the L. (Viannia) subtype, further indication that leishmanial metastasis is caused, at least in part, by a parasitic component. LRV present in this subgenus may contribute to the destructive inflammation of metastatic disease either by acting in concert with other intrinsic "metastatic factors" or by independently preying on host TLR3 hypersensitivity. Because LRV amplifies parasite virulence, its presence may provide a unique target for diagnostic and clinical intervention of metastatic leishmaniasis. Taking examples from other members of the Totiviridae virus family, this paper reviews the benefits and costs of endosymbiosis, specifically for the maintenance of LRV infection in Leishmania parasites, which is often at the expense of its human host.
BibTeX
@inproceedings{hartley2012leishmania,
  author = {Mary‐Anne Hartley and Catherine Ronet and Haroun Zangger and Stephen M. Beverley and Nicolás Fasel},
  title = {{Leishmania RNA virus: when the host pays the toll}},
  booktitle = {Frontiers in Cellular and Infection Microbiology},
  year = {2012},
  doi = {10.3389/fcimb.2012.00099},
}
Figure